1 / 63

Fatty Liver Disease

Fatty Liver Disease. Jamie Blazek, MPH, APRN, FNP-C Liver Transplant Department Ochsner Health Systems New Orleans, La. Disclosures. None. Objectives. Identify risk factors for fatty liver disease Order appropriate screening tests Diagnose and treat fatty liver disease

riordan
Télécharger la présentation

Fatty Liver Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Fatty Liver Disease Jamie Blazek, MPH, APRN, FNP-C Liver Transplant Department Ochsner Health Systems New Orleans, La

  2. Disclosures None

  3. Objectives • Identify risk factors for fatty liver disease • Order appropriate screening tests • Diagnose and treat fatty liver disease • Initiate appropriate referrals

  4. Terminology • ALD: Alcoholic Liver Disease Significant alcohol consumption* > 21 drinks/week for males > 14 drinks/weeks for females • NAFLD: Non-Alcoholic Fatty Liver Disease steatosis without hepatocyte injury • NASH: Non-Alcoholic Steatohepatitis steatosis with inflammation, hepatocyte injury with or without fibrosis *Sanyal, et al Hepatology 2011

  5. Fatty liver Normal liver

  6. Statistics • Alcoholic liver disease • 15 million people abuse/overuse ETOH in USA • 90% of those will develop fatty livers • Moderate use with another risk factor • Non-alcoholic liver disease • Most common chronic liver disease in USA • 4th most common reason for liver transplant • Projected to be the most common in 10-20yrs • Up to 20-40% adults • 6 million children

  7. By 2020

  8. Natural History of FLDfatty liver steatohepatitis steatohepatitis + fibrosis steatohepatitis + cirrhosiscryptogenic cirrhosis

  9. Mortality risk: Cirrhotics with NAFLD vs hepatitis C • Sanyal,et al Hepatology 2006: • NAFLD had lower rate of mortality • Yatsuji, et al Gastroenterology and Hepatology 2009: • No difference • Both showed pts with NAFLD at lower risk for HCC than Hepatitis C pts.

  10. Middle age Female gender Over-weight or obese Viral hepatitis Iron overload Medications Rapid weight loss Starvation/refeeding syndrome Reye’s syndrome Auto-immune disease Malnutrition Abetalipoproteinemia Overgrowth of bacteria in small intestines TPN Acute fatty liver of pregnancy HELLP syndrome Hispanic ethnicity Hereditary NAFLD: risk factors

  11. Risk factors: Established association • Obesity • Type 2 DM: insulin resistance (IR) • Dyslipidemia • Metabolic syndrome (MS)

  12. Risk factors: Emerging association • Polycystic ovary syndrome • Hypothyroidism • Obstructive sleep apnea • Hypopituitarism • Hypogonadism • Pancreatic-duodenal resection

  13. Risk factor: Medications • Amiodarone • Methotrexate • Tamoxifen • Corticosteroids • Diltiazem • Valproic acid • Highly active antiretroviral therapy

  14. Risk factor: Bacteria overgrowth • Grieco, et al. Hepatology 2009 • 35 pts with NAFLD bx confirmed • 27 pts with celiac disease • 24 healthy individuals • Those with FLD had increased intestinal permeability and increased small bowel bacterial overgrowth • Compare, et al Nutrition Metabolism & Cardiovascular Disease Feb 2012 • Liver is 1st line of defense against gut-derived antigens • Levels of bacterial lipopolysaccharide (component of GN bacteria) are increased in the circulation in several types of chronic liver disease • Can modulation of gut microbia represent a new way to treat/prevent NAFLD????

  15. Screening ConsiderationsAASLD rec’s • Liver biochemistries can be normal • Ultrasounds are expensive • General population screening not recommended • Undergoing surgical procedure? • Planned pregnancy with obese mother? • Systematic screening of family members: not recommended at this time

  16. Further work-up indicated • Incidental finding on imaging for some other reason • Abnormal liver enzymes • Symptoms of liver disease • Rule out other causes: alcohol, medications, hepatitis, etc.

  17. Albumin AST ALT NAFLD fibrosis score http://nafldscore.com Age BMI Hyperglycemia Platelet count

  18. NAFLD fibrosis score • < -1.455: predictor of absence of significant fibrosis (F0-F2 fibrosis) • ≤ -1.455 to ≤ 0.675: indeterminate score • > 0.675: predictor of presence of significant fibrosis (F3-F4 fibrosis)

  19. Algorithm for evaluating NAFLD**taken from AGA position paper 2002 Accidental discovery Screen those with risk factors AST or AST Symptomatic liver disease elevated normal r/o other causes of liver disease monitor ongoing alcohol yes no Abstain Imaging study Echogenic US or fat on CT May need biopsy

  20. Liver biopsyAASLD rec’s • Incidental finding on imagery with normal enzymes: no biopsy indicated, monitor. • Presence of metabolic syndrome and persistently elevated biochemistries may benefit from liver biopsy • Patients with biopsy proven NASH cirrhosis should be screened routinely for esophageal varices and HCC

  21. Assessment • Symptoms • Malaise, fatigue, RUQ discomfort • Snores, disturbed sleep, wakes up tired • Chronic pain disorders, achy muscles • Physical exam • Abdominal obesity • Enlarged liver • RUQ tenderness on palpation • Labs • Consistent with metabolic syndrome • Elevated bilirubin, AST, ALT, AP, GGT

  22. Management: Lifestyle Interventions

  23. Weight loss by lower caloric intake and increased physical exercise * led to improvement in biopsy. 9.3% weight loss: improvement in steatosis, necrosis, and inflammation; not fibrosis 3-5% weight loss improves steatosis but more is needed to improve inflammation Alcohol consumption: heavy intake should be avoided light intake (<1/day) may have benefits**, may not*** * Promrat, et al. Hepatology 2010 ** Dunn, et al. Hepatology 2008 ** Gunji. et al. Am J Gastro 2009 ** Moriya, et al. Alim Pharm Ther 2011 ***Ruhl , et al. Clin Gastro Hepatol 2005 Lifestyle Interventions

  24. ManagementMedications

  25. Insulin sensitizing agents • Metformin * • reduction in IR and enzymes, • no improvement in histology • Thiazolidinediones • Rosiglitazone**: improved enzymes and steatosis, but not inflammation • Pioglitazone:***+weight gain, but improvement in hepatocellular injury *Uygun, et alAliment Pharm Ther 2004 *Nair, et alAliment Pharm Ther 2004 **Ratziu, et alGastroenterology 2008 ***Sanyal, et alNE J Med 2010

  26. PIVENS Study • Pioglitazone , Vitamin E, placebo • 96 weeks • Adults • with NASH • without DM, cirrhosis, Hep C, heart failure • limited alcohol intake over previous 5 years • Randomized trial • Pio group: 80 • Vit E group: 84 • Placebo: 83 Sanyal et al,New England J of Medicine 2010

  27. Primary outcome Vitamin E vs placebo 43% improvement vs 19%: significant (Steatosis, lobular inflammation, hepatocellular ballooning and fibrosis) Pio vs placebo 34% improvement vs 19%: not significant Sanyal et al,New England J of Medicine 2010

  28. Secondary outcome • Vitamin E vs placebo • Also reduction in SGOT/SGPT • Pio vs placebo • Reduction in SGOT/SGPT • Reduction in steatosis, lobular inflammation • Improvement in IR • Increase in weight that did not resolve after discontinuance of Pio Sanyal et al,New EngJ of Med 2010

  29. PIVEN Conclusions • Vitamin E was superior to placebo in adults with NASH and without DM • Pioglitazone may have a role in treating patients with biopsy-proven NASH, however long term safety and efficacy has not been established Sanyal et al,New EnglJ of Med 2010

  30. AASLD recommendations: • Pio can be used to treat certain patients with biopsy-proven NASH who do not have DM but long term safety and efficacy has not been established • Vitamin E 800 IU/day improves liver histology in NASH pts • Not recommended to treat NASH in those with other chronic liver diseases, diabetics, those with NASH cirrhosis or cryptogenic cirrhosis, NAFLD without biopsy

  31. Vitamin E: other concerns • Meta-analysis* including 136,000 participants found taking Vitamin E supplements > 400 IU/day had a higher risk of all cause mortality • Vitamin E** > 400 IU/day increases risk of prostate cancer in relatively healthy men *Miller et al Annals of Internal Medicine 2005 ** Klein, et al, JAMA 2011

  32. Other meds for NASH • Ursodeoxycholic acid* • no histologic benefit • Omega-3 fatty acids** • Effective in treating hypertriglyceridemia in pts with NAFLD • Evidence for treatment of NASH inconclusive to date • Large multi-center trial on-going now *Lindor, et al. Hepatology 2004 **Capanni, et al. Alimen Pharm Ther 2006

  33. Statins • CVD common cause of death for NAFLD and NASH • Stratify risks and treat accordingly • Several studies show NAFLD and NASH pts are not at increased risk of liver injury over general population* • No RCTs with histological end points using statins to treat NASH *Chalasani, et al. Am J Gastro 2012

  34. GREACE study* Concluded statins significantly improve liver biochemistries and CV outcomes in pts with elevated enzymes likely due to NASH • Athyros et al Lancet 2010

  35. AASLD Recommendation on Statins “Given lack of evidence that patients with NAFLD and NASH are at increased risk for serious drug-induced liver injury from statins, they can be used to treat dyslipidemia in patients with NAFLD and NASH.”

  36. Bariatric surgery • No RCTs • Cochrane review 2010: lack of RCTs prevents definitive assessment of risks/benefits • Prospective study* • 381 adults with severe obesity, fibrosis score<3 • Clinical, metabolic, liver biopsy comparisons at 1 year and 5 years • Significant improvement in steatosis, ballooning, resolution of probable/definite NASH at 1 and 5 years • Small but significant increase of fibrosis score at 5 years (96% had improvement) *Mathurin et al Gastroenterology 2009

  37. AASLD Recommendation on Bariatric Surgery • Premature to consider foregut surgery as an option to specifically treat NASH • Foregut surgery is not contra-indicated in otherwise eligible pts with NASH or NAFLD WITHOUT cirrhosis • For those with cirrhosis: type, safety and efficacy of foregut surgery is not established

  38. Transplant Considerations

  39. MS & Immunosuppression • Steroids • BP induce IR • lipid metabolism weight gain • gluconeogenesis peripheral glucose utilization • CNIs : pancreatic beta cell toxicity • Nephrotoxicity • TAC - glucose intolerance and de novo DM • CSA - HTN and hyperlipdemia • mTOR inhibitors • hyperlipidemia

  40. Metabolic Syndrome in Kidney Transplant* • Metabolic syndrome (MS) may play a role in allograft loss and poor function • Pathophysiology of MS is altered by immunosuppression * Hricik, Clin J of ASN 2011

  41. Metabolic Syndrome in Kidney Transplant • Prevalence of MS post KTx • 22.6% at 1 year* • 37.7% at 18 months* • 63% at a median of 6 years** * Porrini et al, Amer J of Kid Dis 2006 ** de Vries et al, Amer J of Trans 2004

  42. Metabolic Syndrome in Kidney Transplant • MS lowered creatinine clearance by 5mL/min after 7 years • Systolic BP and hypertriglyceridemia had most negative impact *de Vries et al, Amer J of Trans 2004

  43. Metabolic Syndrome in Kidney Transplant: Blood Pressure Choice of antihypertensive post KTx: Cochrane Group Review http://summaries.cochrane.org/CD003598/ blood-pressure-medication-for-kidney- transplant-recipients

  44. Metabolic Syndrome in Kidney Transplant: Hyperlipdemia • ALERT trial* • Randomized, double blind, placebo control (N=1100) • Fluvastatin was superior to placebo in significantly lowering total and LDL cholesterol in renal transplant pts and in lowering rates of cardiac death and MI • Hypertriglyceridemia: anecdotal use of fenofibric acid, fish oils, ezetimibe *Fellstrom et al Kid Internat 2004

  45. Risk factors for NASH after liver transplant* • Post transplant obesity • TAC based regimen • DM • Hyperglycemia • HTN • ETOH as primary cause for transplant • Pre-transplant allograft biopsy showing steatosis *Dumortier, et al Am J of Gastro March 2010

  46. MS Post Liver Transplant • 44-58% of pts > 6months post OLT • BMI increase of 10% increases risk of post OLT NAFLD • Associated with increased cardiovascular and cerebrovascular events • CVD causes 19-42% non-liver related deaths • Diabetes, HTN, IR add 2-fold increased mortality risk Watt & Charlton J Hepatology 2010

  47. MS Post Liver Transplant • Obesity • Between 1990 and 2002 the % of obese OLT recipients increased from 15% to 25% and average increase of 1kg/year* • Orlistat (tetrahydrolipstatin)** Limited efficacy • May interfere with drug absorption • Post transplant bariatric surgery: few reported cases*** • May interfere with drug absorption * Everhart et al, Liver Transpl Surg 1998 * Richards et al, Transpl Int 2005 ** Cassiman et al, Transpl Int 2006 ***Takata et al, Surg Obes Relat Dis 2008 *** Butte et al, Obes Surg 2007 *** Campsen et al, Obes Surg 2008

  48. MS Post Liver Transplant* • Diabetes post OLT • 5 year occurrence of advanced fibrosis is increased in patients treated for DM (49%) when compared to those with normal insulin sensitivity (20%) • Treatment goals same as general population * Watt & Charlton J Hepatology 2010

  49. MS Post Liver Transplant* • Dyslipidemia post OLT: 45-69% • Changing immunosuppression: CsA to TAC, Rapa to TAC, steroid free • High cholesterol: Statins: • pravastatin most studied; does not require P450 enzyme system • With other statins: reduction in TAC/CsA dose??? • Mediterranean diet • High Triglycerides: • fish oils • Fenofibric acids derivatives: reduction in TAC/CsA dose??? • ezetimide * Watt & Charlton J Hepatology 2010

  50. MS and Heart Transplant* 48% of heart transplant recipients Long term survival better without MS • Differences observed in MS group • Median age older • Pre-tx creatinine higher • Pre-tx HTN higher • BMI higher • Dyslipidemia higher rate • No difference MS vs nonMS • Gender • Underlying etiology • Smoking • DM history pre-tx • Immunosuppression *Sanchez-Lazaro et al Transplantation Proc 2011

More Related